Gupta, S., Yang, Q., Halabi, S., Tubbs, A., Gore, Y., George, D. J., … Armstrong, A. J. (2022). 1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC). In Annals of Oncology (Vol. 33, pp. S1165–S1166). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1497

Gupta, S., Q. Yang, S. Halabi, A. Tubbs, Y. Gore, D. J. George, D. M. Nanus, et al. “1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC).” In Annals of Oncology, 33:S1165–66. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1497.

Gupta S, Yang Q, Halabi S, Tubbs A, Gore Y, George DJ, et al. 1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC). In: Annals of Oncology. Elsevier BV; 2022. p. S1165–6.

Gupta, S., et al. “1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1165–66. Crossref, doi:10.1016/j.annonc.2022.07.1497.

Gupta S, Yang Q, Halabi S, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila D, Szmulewitz R, Wenstrup RJ, Armstrong AJ. 1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC). Annals of Oncology. Elsevier BV; 2022. p. S1165–S1166.